{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:41:56Z","timestamp":1791333716749,"version":"4.3.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ebiom.2022.104158","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T05:45:21Z","timestamp":1657518321000},"page":"104158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"special_numbering":"C","title":["Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-3376","authenticated-orcid":false,"given":"Alexander","family":"Wilhelm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-9307","authenticated-orcid":false,"given":"Marek","family":"Widera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Grikscheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5399-9263","authenticated-orcid":false,"given":"Tuna","family":"Toptan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7925-5529","authenticated-orcid":false,"given":"Melinda","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Kohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hoehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Marschalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian A.","family":"Helfritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-9540","authenticated-orcid":false,"given":"Timo","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Goetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-7598","authenticated-orcid":false,"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.ebiom.2022.104158_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104158_bib0002","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel Coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104158_bib0003","series-title":"Emergency Situation Updates","article-title":"COVID-19 Weekly Epidemiological Update on COVID-19","year":"2022"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104158_bib0004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104158_bib0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"7902","key":"10.1016\/j.ebiom.2022.104158_bib0006","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"issue":"10325","key":"10.1016\/j.ebiom.2022.104158_bib0007","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","author":"Kuhlmann","year":"2022","journal-title":"Lancet"},{"issue":"7854","key":"10.1016\/j.ebiom.2022.104158_bib0008","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"issue":"6593","key":"10.1016\/j.ebiom.2022.104158_bib0009","doi-asserted-by":"crossref","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104158_bib0010","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jmv.27558","article-title":"Mutational and phylogenetic analyses of the two lineages of the Omicron variant","volume":"94","author":"Majumdar","year":"2022","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104158_bib0011","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/jmv.27516","article-title":"Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa","volume":"94","author":"Wang","year":"2022","journal-title":"J Med Virol"},{"issue":"7839","key":"10.1016\/j.ebiom.2022.104158_bib0012","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.ebiom.2022.104158_bib0013","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMc2114706","article-title":"Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104158_bib0014","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/infdis\/jiab355","article-title":"Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro","volume":"224","author":"Widera","year":"2021","journal-title":"J Infect Dis"},{"issue":"7898","key":"10.1016\/j.ebiom.2022.104158_bib0015","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.ebiom.2022.104158_bib0016","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.ebiom.2022.104158_bib0017","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"10.1016\/j.ebiom.2022.104158_bib0018","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104158_bib0019","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons","volume":"386","author":"Rossler","year":"2022","journal-title":"N Engl J Med"},{"issue":"6581","key":"10.1016\/j.ebiom.2022.104158_bib0020","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"issue":"10321","key":"10.1016\/j.ebiom.2022.104158_bib0021","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet"},{"issue":"7898","key":"10.1016\/j.ebiom.2022.104158_bib0022","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron","volume":"602","author":"Carreno","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104158_bib0023","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/v14020294","article-title":"The Spread of SARS-CoV-2 variant Omicron with a doubling time of 2.0-3.3 days can be explained by immune evasion","volume":"14","author":"Grabowski","year":"2022","journal-title":"Viruse"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104158_bib0024","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2022.104158_bib0025","article-title":"COVID-19 Vaccines: \u201cWarp Speed\u201d needs mind melds, not warped minds","volume":"94","author":"Moore","year":"2020"},{"issue":"6578","key":"10.1016\/j.ebiom.2022.104158_bib0026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.abm0620","article-title":"SARS-CoV-2 vaccine protection and deaths among US veterans during 2021","volume":"375","author":"Cohn","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104158_bib0027","series-title":"Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19\u2013Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance \u2014 VISION Network, 10 States","year":"2022"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104158_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/v13091693","article-title":"Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K\/E484Q","volume":"13","author":"Wilhelm","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ebiom.2022.104158_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2022.883724","article-title":"Low but recoverable markers of humoral immune response to BNT162b2 in Elderly LTCF residents five to seven months after two-dose vaccination","volume":"3","author":"Delbr\u00fcck","year":"2022","journal-title":"Front Aging"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104158_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124396","article-title":"Optimized qRT-PCR approach for the detection of intra- and extra-cellular SARS-CoV-2 RNAs","volume":"21","author":"Toptan","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2034","key":"10.1016\/j.ebiom.2022.104158_bib0031","article-title":"Generation of a sleeping beauty transposon-based cellular system for rapid and sensitive screening for compounds and cellular factors limiting SARS-CoV-2 replication","volume":"12","author":"Widera","year":"2021","journal-title":"Front Microbiol"},{"issue":"7816","key":"10.1016\/j.ebiom.2022.104158_bib0032","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41586-020-2332-7","article-title":"Proteomics of SARS-CoV-2-infected host cells reveals therapy targets","volume":"583","author":"Bojkova","year":"2020","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ebiom.2022.104158_bib0033","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00018-004-4222-9","article-title":"Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus","volume":"61","author":"Cinatl","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104158_bib0034","first-page":"227","article-title":"The method of right and wrong cases (constant stimuli) without Gauss's formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br J Psychol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104158_bib0035","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr Experimentelle Pathologie und Pharmakologie"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104158_bib0036","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00430-021-00716-3","article-title":"Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings","volume":"210","author":"Widera","year":"2021","journal-title":"Med Microbiol Immunol"},{"issue":"7902","key":"10.1016\/j.ebiom.2022.104158_bib0037","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104158_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104158_bib0039","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Stamatatos","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104158_bib0040","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","article-title":"Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals","volume":"27","author":"Kustin","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104158_bib0041","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104158_bib0042","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1038\/s41467-021-23473-6","article-title":"Immune response to SARS-CoV-2 variants of concern in vaccinated individuals","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"issue":"7857","key":"10.1016\/j.ebiom.2022.104158_bib0043","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ebiom.2022.104158_bib0044","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104158_bib0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'Kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104158_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2022.03.004","article-title":"Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters","volume":"3","author":"McMahan","year":"2022","journal-title":"Med"},{"issue":"7902","key":"10.1016\/j.ebiom.2022.104158_bib0047","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","article-title":"Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron","volume":"603","author":"Shuai","year":"2022","journal-title":"Nature"},{"issue":"7902","key":"10.1016\/j.ebiom.2022.104158_bib0048","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.ebiom.2022.104158_bib0049","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106267","article-title":"Syncytia formation by SARS-CoV-2-infected cells","volume":"39","author":"Buchrieser","year":"2020","journal-title":"EMBO J"},{"issue":"6582","key":"10.1016\/j.ebiom.2022.104158_bib0050","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1126\/science.abn7760","article-title":"SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex","volume":"375","author":"Mannar","year":"2022","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.ebiom.2022.104158_bib0051","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"Yu","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104158_bib0052","article-title":"Mapping SARS-CoV-2 antigenic relationships and serological responses","author":"Wilks","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.ebiom.2022.104158_bib0053","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","author":"Tseng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104158_bib0054","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2","author":"Cathcart","year":"2022","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104158_bib0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"issue":"7906","key":"10.1016\/j.ebiom.2022.104158_bib0056","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104158_bib0057","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","article-title":"Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ebiom.2022.104158_bib0058","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-dependent cellular phagocytosis in antiviral immune responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104158_bib0059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247640","article-title":"Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma","volume":"16","author":"Tso","year":"2021","journal-title":"PLoS One"},{"issue":"7901","key":"10.1016\/j.ebiom.2022.104158_bib0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"issue":"69","key":"10.1016\/j.ebiom.2022.104158_bib0061","doi-asserted-by":"crossref","first-page":"eabo2202","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci Immunol"},{"issue":"7901","key":"10.1016\/j.ebiom.2022.104158_bib0062","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104158_bib0063","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41564-021-01046-z","article-title":"Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults","volume":"7","author":"Romero-Olmedo","year":"2022","journal-title":"Nat Microbiol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422003395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422003395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:21:11Z","timestamp":1762456871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422003395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":63,"alternative-id":["S2352396422003395"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104158","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.07.21267432","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104158"}}